(Q46598462)

23 December 2017

title

Racial differences in potassium response to spironolactone in heart failure (English)

1 reference

23 December 2017

author name string

Larisa H Cavallari

1

1 reference

23 December 2017

Vicki L Groo

2

1 reference

23 December 2017

Kathryn M Momary

3

1 reference

23 December 2017

Deidra Fontana

4

1 reference

23 December 2017

Marlos Ag Viana

5

1 reference

23 December 2017

Paul Vaitkus

6

1 reference

23 December 2017

publication date

1 July 2006

1 reference

23 December 2017

published in

Congestive Heart Failure

1 reference

23 December 2017

volume

12

1 reference

23 December 2017

issue

4

1 reference

23 December 2017

page(s)

200-205

1 reference

23 December 2017

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2006.05502.X

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2006.05502.X

Racial differences in potassium disposal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2006.05502.X

Genetic influences on the urinary excretion of aldosterone in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2006.05502.X

Regulation of aldosterone secretion in hypertensive blacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2006.05502.X

Ethnicity and unprovoked hypokalemia in the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2006.05502.X

Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2006.05502.X

Hyperkalemia after the publication of RALES.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2006.05502.X

Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2006.05502.X

Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2006.05502.X

Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2006.05502.X

Mechanisms and models in heart failure: the biomechanical model and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2006.05502.X

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2006.05502.X

Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-5299.2006.05502.X

10.1111/J.1527-5299.2006.05502.X

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017